On 2017 ASCO meeting, Professor Wu Yilong, from Guangdong Provincial People's Hospital in China, showed a heavy clinical data: for mid-term lung cancer after surgical resection, the use of targeted drug gefitinib, compared to adjuvant chemotherapy, can delay tumor recurrence time for about 10 months, and the risk of recurrence decreased by 40%.
Anti-cancer targeted drug major breakthrough, generally begin to do clinical trails from the late stage of the tumor, very few initially from early tumors. Late tumors, often no drug can be effective. After application of advanced cancer clinical had good results, the target drug was slowly considered for early and middle stage cancer. Treatment goals transfer from late cancer to moderate anti-cancer, gradually to the early cure of anti-cancer, which has always been our ultimate desire.
Take lung cancer, after the medium (II-IIIA) non-small cell lung cancer surgery, the risk of recurrence is high, seriously affecting the long-term survival of patients, 5-year survival rate of only 40%. Among all non-small cell lung cancer patients, about 25% of patients are eligible for radical surgery, of which about 30% are with EGFR mutant tumors, theoretically may benefit from EGFR targeted therapy.
From this aspect, not only advanced lung cancer need a good target drug, early and mid-lung cancer also need a good treatment to improve efficacy. Lung cancer surgery, even if the tumor is cut very clean, the inspection data is normal. In fact, there are still a small amount of residual cancer cells, but can not be detected any more. In this case, it is necessary to use appropriate treatments such as medications (postoperative adjuvant therapy) to prevent the recurrence of these residual residual cancer cells after surgery.
Any interest about pharmaceutical products, please contact: info@tiankunchem.com
